YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company is advancing two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF™, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.
Watch David Allan's German TV interview on Deutsches Anleger Fernsehen (February 2008)

Upcoming Events
BioFinance
Toronto Marriott Eaton Centre Hotel (Trinity I room) - Toronto, ON
When: May 7, 2008 9:30a.m. EDT
Presenter: David Allan, Chairman and CEO
American Society of Pediatric Hematology/Oncology (ASPHO) Annual Meeting
Duke Energy Center & Hyatt Regency - Cincinnati, OH
When: May 15-16, 2008
Exhibit #508